Zymeworks (ZYME) Operating Income (2021 - 2026)
Zymeworks recorded quarterly Operating Income of -$47.1 million in Q1 2026, down 6.72% quarter-over-quarter from -$44.2 million in Q4 2025, and down 83.96% year-over-year from -$293.8 million in Q1 2025.
Zymeworks' Operating Income history runs 6 years deep, the most recent figure standing at -$47.1 million for Q1 2026.
- In Q1 2026, Operating Income fell 83.96% year-over-year to -$47.1 million; the TTM figure through Mar 2026 stood at -$114.1 million (up 8.7% YoY), while the FY2025 annual figure was -$92.5 million, up 32.5% from the prior year.
- Operating Income came in at -$47.1 million for Q1 2026 at Zymeworks, down from -$44.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $319.4 million in Q4 2022 to a low of -$72.7 million in Q1 2022.
- A 5-year average of -$16.7 million and a median of -$34.2 million in 2024 frame the typical range for Operating Income.
- Across the five-year window, Operating Income surged 881.89% in 2022 and slumped 107.33% in 2023, its largest moves.
- Zymeworks' Operating Income stood at $319.4 million in 2022, then tumbled by 107.33% to -$23.4 million in 2023, then gained by 5.14% to -$22.2 million in 2024, then sank by 98.73% to -$44.2 million in 2025, then decreased by 6.72% to -$47.1 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$47.1 million, -$44.2 million, and -$22.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | -47.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.12 Mn |
| Dec 31, 2025 | -44.15 Mn |
| Sep 30, 2025 | -22.11 Mn |
| Jun 30, 2025 | -674,000.00 |
| Mar 31, 2025 | -25.61 Mn |
| Dec 31, 2024 | -22.22 Mn |
| Sep 30, 2024 | -34.21 Mn |
| Jun 30, 2024 | -42.89 Mn |
| Mar 31, 2024 | -37.80 Mn |
| Dec 31, 2023 | -23.42 Mn |
| Sep 30, 2023 | -33.24 Mn |
| Jun 30, 2023 | -54.11 Mn |
| Mar 31, 2023 | -27.28 Mn |
| Dec 31, 2022 | 319.40 Mn |
| Sep 30, 2022 | -50.36 Mn |
| Jun 30, 2022 | -65.82 Mn |
| Mar 31, 2022 | -72.69 Mn |
| Dec 31, 2021 | -40.85 Mn |
| Sep 30, 2021 | -60.96 Mn |